Dusp1 in osteolytic diseases-mechanisms and therapeutic potential

Abstract Osteolytic diseases are a significant and escalating global public health issue, driven by the acceleration of population aging and the rising incidence of degenerative, metabolic, and neoplastic diseases. The primary therapeutic strategy for osteolytic diseases is to suppress the bone reso...

Full description

Saved in:
Bibliographic Details
Main Authors: Boyu Liu, Ming Lei, Baicheng Wan, Yanbing Feng, Yilin Teng, Deshuang Xi, Shou Chen, Gaofeng Zeng, Shaohui Zong
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-05142-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849238790576537600
author Boyu Liu
Ming Lei
Baicheng Wan
Yanbing Feng
Yilin Teng
Deshuang Xi
Shou Chen
Gaofeng Zeng
Shaohui Zong
author_facet Boyu Liu
Ming Lei
Baicheng Wan
Yanbing Feng
Yilin Teng
Deshuang Xi
Shou Chen
Gaofeng Zeng
Shaohui Zong
author_sort Boyu Liu
collection DOAJ
description Abstract Osteolytic diseases are a significant and escalating global public health issue, driven by the acceleration of population aging and the rising incidence of degenerative, metabolic, and neoplastic diseases. The primary therapeutic strategy for osteolytic diseases is to suppress the bone resorption activity of osteoclasts. Dusp1 is a member of the serine/threonine inducible nuclear phosphatase family and has significant anti-inflammatory effects. In this study, Dusp1 overexpression was induced via lentiviral transfection. We found that Dusp1 antagonized RANKL stimulation, mediated the MAPK signaling pathway, and downregulated the key downstream transcription factors c-FOS and NFATc1, thereby reducing the expression of osteoclast-specific genes. Furthermore, Dusp1 reduced the number and activity of osteoclasts both in vivo and in vitro, leading to a diminished bone resorption function. In addition, the results of animal experiments demonstrated that Dusp1 protected mice from LPS-induced skull osteolysis. Overall, our study reveals that Dusp1 suppresses osteoclast formation and activity by downregulating the MAPK/c-FOS/NFATc1 signaling pathway. These findings suggest the potential of Dusp1 to protect against osteolytic diseases.
format Article
id doaj-art-b955c9202b994ded8eaece5fb51cddf8
institution Kabale University
issn 2045-2322
language English
publishDate 2025-07-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-b955c9202b994ded8eaece5fb51cddf82025-08-20T04:01:24ZengNature PortfolioScientific Reports2045-23222025-07-0115111510.1038/s41598-025-05142-6Dusp1 in osteolytic diseases-mechanisms and therapeutic potentialBoyu Liu0Ming Lei1Baicheng Wan2Yanbing Feng3Yilin Teng4Deshuang Xi5Shou Chen6Gaofeng Zeng7Shaohui Zong8Department of Spine Osteopathia, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical UniversityDepartment of Spine Osteopathia, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical UniversityDepartment of Spine Osteopathia, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical UniversityDepartment of Spine Osteopathia, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical UniversityDepartment of Spine Osteopathia, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical UniversityDepartment of Spine Osteopathia, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical UniversityDepartment of Spine Osteopathia, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical UniversityDepartment of Nutrition and Food Hygiene, College of Public Hygiene of Guangxi Medical UniversityDepartment of Spine Osteopathia, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical UniversityAbstract Osteolytic diseases are a significant and escalating global public health issue, driven by the acceleration of population aging and the rising incidence of degenerative, metabolic, and neoplastic diseases. The primary therapeutic strategy for osteolytic diseases is to suppress the bone resorption activity of osteoclasts. Dusp1 is a member of the serine/threonine inducible nuclear phosphatase family and has significant anti-inflammatory effects. In this study, Dusp1 overexpression was induced via lentiviral transfection. We found that Dusp1 antagonized RANKL stimulation, mediated the MAPK signaling pathway, and downregulated the key downstream transcription factors c-FOS and NFATc1, thereby reducing the expression of osteoclast-specific genes. Furthermore, Dusp1 reduced the number and activity of osteoclasts both in vivo and in vitro, leading to a diminished bone resorption function. In addition, the results of animal experiments demonstrated that Dusp1 protected mice from LPS-induced skull osteolysis. Overall, our study reveals that Dusp1 suppresses osteoclast formation and activity by downregulating the MAPK/c-FOS/NFATc1 signaling pathway. These findings suggest the potential of Dusp1 to protect against osteolytic diseases.https://doi.org/10.1038/s41598-025-05142-6Dusp1OverexpressionLentivirusOsteoclastOsteolysisMAPK
spellingShingle Boyu Liu
Ming Lei
Baicheng Wan
Yanbing Feng
Yilin Teng
Deshuang Xi
Shou Chen
Gaofeng Zeng
Shaohui Zong
Dusp1 in osteolytic diseases-mechanisms and therapeutic potential
Scientific Reports
Dusp1
Overexpression
Lentivirus
Osteoclast
Osteolysis
MAPK
title Dusp1 in osteolytic diseases-mechanisms and therapeutic potential
title_full Dusp1 in osteolytic diseases-mechanisms and therapeutic potential
title_fullStr Dusp1 in osteolytic diseases-mechanisms and therapeutic potential
title_full_unstemmed Dusp1 in osteolytic diseases-mechanisms and therapeutic potential
title_short Dusp1 in osteolytic diseases-mechanisms and therapeutic potential
title_sort dusp1 in osteolytic diseases mechanisms and therapeutic potential
topic Dusp1
Overexpression
Lentivirus
Osteoclast
Osteolysis
MAPK
url https://doi.org/10.1038/s41598-025-05142-6
work_keys_str_mv AT boyuliu dusp1inosteolyticdiseasesmechanismsandtherapeuticpotential
AT minglei dusp1inosteolyticdiseasesmechanismsandtherapeuticpotential
AT baichengwan dusp1inosteolyticdiseasesmechanismsandtherapeuticpotential
AT yanbingfeng dusp1inosteolyticdiseasesmechanismsandtherapeuticpotential
AT yilinteng dusp1inosteolyticdiseasesmechanismsandtherapeuticpotential
AT deshuangxi dusp1inosteolyticdiseasesmechanismsandtherapeuticpotential
AT shouchen dusp1inosteolyticdiseasesmechanismsandtherapeuticpotential
AT gaofengzeng dusp1inosteolyticdiseasesmechanismsandtherapeuticpotential
AT shaohuizong dusp1inosteolyticdiseasesmechanismsandtherapeuticpotential